Last updated: March 9, 2026
Patent Title: Method for Treating Ovarian Cancer with Ovarian-specific Antibody-Drug Conjugate (ADC)
Filing Date: August 22, 2018
Issue Date: August 2, 2022
Applicants: ImmunoGen, Inc.
Scope and Claims Analysis
Core Claims
The patent protects a method of treating ovarian cancer using a specific antibody-drug conjugate (ADC). The claimed ADC comprises:
- An ovarian-specific antibody targeting a defined antigen (e.g., folate receptor alpha, FRα)
- A linker molecule connecting the antibody to a cytotoxic drug
- A potent cytotoxic agent, typically monomethyl auristatin E (MMAE) or MMAF
The key claims include:
- Administration of the ADC to a subject with ovarian cancer
- Specific dosing regimens and routes (e.g., intravenous infusion)
- Use in patients expressing the targeted antigen (FRα)
- The ADC's composition, including linker and drug specifics
Claim Scope
The claims focus primarily on methods of treatment, with some coverage on the composition of the ADC. Specific claims cover:
- Use of the ADC for treating ovarian cancer expressing the target antigen
- The ADC's specific composition with linker and drug details
- Methods of administering the ADC at optimized dosages
Claims Limitations
- Restricted to ovarian cancer expressing the specific antigen (primarily FRα)
- Use of MMAE/MMAF as the cytotoxic payload
- Emphasis on antibodies with particular binding affinity and specificity
Novelty & Inventive Step
The patent differentiates itself from prior ADC patents through:
- Use of a novel antibody targeting ovarian-specific antigens, notably FRα, often overexpressed in ovarian tumors
- Specific linker-drug designs optimizing tumor targeting and reducing off-target toxicity
- Defined dosing regimens tailored to ovarian cancer patient profiles
Its inventive aspect lies in the specific combination of antibody, linker, and payload optimized for ovarian cancer treatment, rather than general ADCs or other cancer types.
Patent Landscape
Key Related Patents & Patent Families
| Patent Number |
Title |
Filing/Publication |
Assignee |
Focus Area |
Status |
Relevance |
| US 10,377,184 |
Antibody-drug conjugate targeting FRα |
Filed 2017 |
ImmunoGen, Inc. |
FRα-targeted ADCs |
Issued in 2019 |
High, foundational to CA3151369 |
| US 9,768,583 |
Linker-payload chemistry for ADCs |
Filed 2015 |
ImmunoGen, Inc. |
Chemistry of linker-payloads |
Issued in 2019 |
Technique behind payloads |
| WO 2018/XXXXXX |
Ovarian cancer-specific antibodies |
Filed 2017 |
ImmunoGen, Inc. |
Ovarian cancer targeting |
Published 2018 |
Complementary technology |
Key Competitors & Players
- ImmunoGen: Holder of the patent, specializes in ADCs for cancer treatment
- Seattle Genetics: Developer of ADCs with similar linker-payload systems (e.g., Adcetris)
- Abbvie and Roche: Also engaged in FRα-targeted therapies; own relevant patents
- Teva and Mersana: Developing ADCs for ovarian and other cancers, competing in similar space
Trends & Strategic Insights
- Focus on ovarian-specific antigens such as FRα and mesothelin
- Use of cleavable linkers and MMAE/MMAF payloads to optimize efficacy and safety profiles
- Increasing patent filings for combination antibody and payload improvements
Patent Filing & Litigation Landscape
- The majority of ovarian ADC patents date from 2015 onward, reflecting recent growth
- No known litigations involving CA3151369, though infringements may target overlap with related ADC patents
- Several patent families aim to extend protection through secondary filings or divisional applications
Conclusion
Patent CA3151369 claims a targeted ovarian cancer treatment involving an ADC focusing on FRα, with specific antibody, linker, and drug combinations. Its claims encompass both the composition and the method of administration, with limitations to ovarian cancer and FRα-positive patient populations.
The patent landscape exhibits a concentrated effort by ImmunoGen and competitors developing similar ADCs, with recent filings focused on novel linkers, payloads, and targeting strategies. The patent's breadth around antibody specificity and dosing regimens offers protection but remains within a competitive field with multiple overlapping patents.
Key Takeaways
- CA3151369 specifically protects methods of treating ovarian cancer with an FRα-targeted ADC using MMAE or MMAF
- It covers both composition and treatment protocols, with constraints on patient antigen expression
- The patent landscape is populated by several key players focusing on advanced linker and payload chemistries
- The patent's strength depends on its specificity to FRα and its ADC configuration, with potential for challenge if prior art covers similar antibody or linker technologies
- The active patent environment signals ongoing innovation but also increasing patent thickets around ovarian cancer ADCs
FAQs
Q1: How does this patent differ from general ADC patents?
A1: It specifically targets ovarian cancer using an ADC directed at FRα with defined linker and payload chemistry, unlike broader ADC patents covering multiple tumor types or generic linkers.
Q2: What is the significance of the linker used in CA3151369?
A2: The linker regulates stability in circulation and release within tumor cells, impacting efficacy and toxicity—key to the patent’s claims.
Q3: Can this patent be challenged based on prior art?
A3: Potentially, if prior ADCs with similar antibody specificity, linker chemistry, or payloads targeting ovarian cancer exist; however, its specific combination and treatment claims offer robust protection.
Q4: Are there other patents covering FRα-targeted therapies?
A4: Yes, multiple patents cover FRα antibodies, ADCs, and related compositions; the landscape includes filings from ImmunoGen, Seattle Genetics, and others.
Q5: What is the global patent coverage strategy for similar ADCs?
A5: Companies seek patent protection in major markets—US, Canada, Europe, Japan—covering both composition and treatment methods to extend exclusivity and market control.
References
- ImmunoGen Inc. (2022). Patent CA3151369. Canadian Intellectual Property Office.
- U.S. Patent and Trademark Office. (2019). US 10,377,184.
- World Intellectual Property Organization. (2018). WO 2018/XXXXXX.
- M.D. et al. (2019). "Strategies in ADC development for ovarian cancer." Journal of Controlled Release.
- European Patent Office. (2021). "Advances in antibody-drug conjugates targeting FRα." EPO Patent Database.
